Total Results: 12067

Doctor’s Murder Raises Tough Questions About Battling Opioid Epidemic

KHN Morning Briefing

Dr. Todd Graham refused to give a patient a pain killer prescription. The woman’s husband returned with threats and a gun. Graham’s death is serving as a stark reminder to the community that doctors are on the front lines of the crisis. Meanwhile, deaths from drug overdoses in the U.S. rose sharply in the first nine months of 2016.

For Insurance Commissioners On Front Lines, Subsidies Aren’t Just A Part Of A Political Game

KHN Morning Briefing

In Washington, the subsidies for insurers have become a hot topic in the health care debates, but state insurance commissioners are more concerned about what they’ll actually have to do if they’re cut off. Without the federal subsidies, insurers would need to get the money — estimated at $7 billion to $10 billion next year — from another source. Meanwhile, in other marketplace news, Anthem is pulling out of Nevada’s exchanges and paring back its offerings in Georgia, and Molina is closing a clinic in Michigan.

As ACA Emerges From The Rubble Intact, Attention Shifts To Enrollment Season

KHN Morning Briefing

Many questions remain about what exactly the enrollment period will look like, and if President Donald Trump and his administration will try to undermine sign-ups. Meanwhile, the damage may already be done to the individual marketplace following months of uncertainty.

Feds Back Down Over Rule Requiring Accreditors To Release Reports On Hospital Errors, Mix-Ups

KHN Morning Briefing

The decision did not go over well with supporters of the rule. ““The public deserves full transparency on how the health care industry performs. Instead, transparency has been sacrificed to accommodate special interests that lobby to avoid disclosing embarrassing information about health care quality,” said Leah Binder, president and CEO of The Leapfrog Group.

Emails Reveal Behind-The-Scenes Drama Of FDA’s Drug Approval Process

KHN Morning Briefing

Last year, a fierce battle emerged over Sarepta’s new muscular dystrophy drug, in which FDA official Janet Woodcock approved the treatment — overruling the recommendations of a review team and an advisory committee. Newly released emails show what happened next.